Refine by
Prostate Cancer Biopsies Articles & Analysis
22 news found
The miR Sentinel™ Prostate Cancer Test is a standalone, non-invasive liquid biopsy urine test that can, from a single urine specimen, accurately detect molecular evidence of prostate cancer and, if cancer is detected, classify the severity, or the risk grade, of the malignancy. ...
Rarecells, Inc. (USA), a leading Liquid Biopsy company, is pleased to announce that National Institute of Integrative Medicine’s (Melbourne, Australia) researchers obtained striking results in a group of Australian men using the ISET® test for early prostate cancer diagnosis through the detection of Prostate-Specific ...
Prostate cancer is the most common type of cancer in men. Every year this diagnosis is made about 900 thousand times, in developed countries the disease affects up to 14% of the entire male population with oncology due to longer life expectancy. We spoke with adult prostate cancer survivors. ...
NEW YORK and SAN JUAN, Puerto Rico, Aug. 18, 2022 /PRNewswire/ -- miR Scientific, LLC announced the launch of national event #CanDoBlue to create awareness of the need for widespread prostate cancer testing during the 2022 Prostate Cancer Awareness Month (also known as "PCAM"). ...
The miR Sentinel™ Test assesses the risk of aggressive prostate cancer and is intended to aid in the clinical management of men >45 years of age at risk for prostate cancer. ...
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its prostate cancer test, IsoPSA, has been added to the National Comprehensive Cancer Network (NCCN) Guidelines for Prostate ...
“We expect that IsoPSA, our novel blood-based prostate cancer test, may fundamentally shift the diagnostic paradigm of prostate cancer, and improve patient care and ...
” The TransMedTech Institute has also made new detection applications of the Raman probe technology possible – in particular, for other types of cancer such as prostate cancer. Prostate cancer is the most common cancer directly affecting men in Canada. The Canadian ...
When comparing the results of the miR Sentinel® Prostate Cancer Test to systematic core needle biopsy in men presenting with initial suspicion of prostate cancer, the latest validation study demonstrated a 93% concordance between the two methods of screening and detection regarding the classification of ...
This urgent awareness team effort occurs while the pioneering cooperation continues, as Puerto Rico has for the past year conducted clinical studies for a prostate cancer liquid biopsy breakthrough test developed by miR Scientific. ...
The second place went to the Turin-based start-up NIB Biotech, that has developed the first rapid urine test for the screening of prostate cancer, capable of contemporary identifying the presence and aggressiveness of a possible case of cancer, helping doctors determine whether a prostate biopsy is necessary. ...
Wiemer et al. 2020, European Urology Focus: Micro-Ultrasound targeted biopsy found a higher-grade cancer in 26% of patients compared to non-targeted samples and MRI targeted samples in this single-center experience. ...
TORONTO, CANADA -- (March 23, 2021) Exact Imaging (www.exactimaging.com), the world’s leader in high resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, announces $5.1M in financing provided by BDC Capital, through the Bridge Financing Program, and Export Development Canada (EDC). ...
Exosome Diagnostics is the world leader in developing exosomal liquid biopsy-based diagnostic assays. The EPI test is a non-invasive, urine-based genomic test that helps inform the prostate biopsy decision. ...
"I will highlight our pioneering cooperation agreement with Puerto Rico along with the need to focus on high-risk and minority patients in need of quick treatment. Our prostate cancer test is a standalone, non-invasive liquid biopsy urine test that can, from a single urine specimen, accurately detect molecular evidence of ...
The publication demonstrates the cost effectiveness and economic utility of Cleveland Diagnostics’ IsoPSA test for the detection of clinically significant prostate cancer. The published analysis projected cost savings of the IsoPSA test based on previous clinical evidence of its effectiveness compared to a standard of care workup to guide the need for a ...
Bio-Techne Corporation (NASDAQ:TECH) today announced an important publication in BMC Urology, entitled A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy (available here). ...
The ExoDx™ Prostate (EPI) test played an important role in the management of Cal's prostate cancer. One in nine American men will be diagnosed with prostate cancer during their lifetime. Prostate cancer (PCa) is the second leading cause of cancer death ...
About Exact Imaging Exact Imaging (www.exactimaging.com) is the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Exact Imaging’s ExactVu™ micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution ...
” Cleveland Diagnostics has concluded two multicenter clinical trials in top U.S. and international hospitals and clinics, led by Cleveland Clinic, in which the diagnostic accuracy of IsoPSA was compared to that of PSA, the current standard of care in prostate cancer, in men scheduled for prostate biopsy. The results from ...